Pre-Test Targeted Therapy Approaches for Metastatic Urothelial Carcinoma Pre-Test Which of the following therapies has an FDA-approved companion diagnostic test to aid in treatment selection and precision therapy? Erdafitinib Enfortumab vedotin Sacituzumab govitecan Sitravatinib Unsure ____________ is a category 1 preferred subsequent-line systemic therapy option in the current NCCN guidelines for locally advanced or metastatic UC previously treated with chemotherapy and anti-PD(L)1 therapy. Sacituzumab govitecan Enfortumab vedotin Nivolumab Atezolizumab Unsure Which of the following strategies is likely to reduce adverse events and help sustain treatment associated with targeted therapy in mUC and should be attempted first? Treatment switch Treatment cessation Dose interruption and/or reduction No change in dose Unsure
